This site is intended for health professionals only
Saturday 23 June 2018
Share |

Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA and FDA regulatory review

Related articles

A report from the charity Cancer Research UK has called on the health service to prepare for a large increase in the number of over 75s with cancer
Global pharmaceutical company to discontinue a late-stage trial assessing the efficacy of an experimental therapy in reducing chronic cluster headaches.
Manufacturer Amgen has received approval from the European Commission (EC) to include overall survival (OS) data on the labels of the drug BLINCYTO (blinatumomab), it has announced.

Boehringer Ingelheim has announced that BI 695501, its adalimumab biosimilar candidate to Humira®, has been accepted for regulatory review by the European Medicines Agency (EMA) and the U.S Food and Drug Administration (FDA). 

 

 

 

 

 

 

Ads by Google